---
title: "Can-Fite BioPharma (CANF) Soars 52% on Phase 2a Cancer Drug Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291431413.md"
description: "Can-Fite BioPharma rises 52% after Phase 2a Namodenoson trial meets safety endpoint with durable survival results."
datetime: "2026-07-01T14:20:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291431413.md)
  - [en](https://longbridge.com/en/news/291431413.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291431413.md)
---

# Can-Fite BioPharma (CANF) Soars 52% on Phase 2a Cancer Drug Results

Can-Fite BioPharma(CANF.US) 盘中涨超 52%，现报 4.515 美元。

公司宣布其评估 Namodenoson 治疗晚期胰腺导管腺癌患者的二期 a 阶段研究达成主要安全性终点，并展现出持久的总生存期结果。该利好消息推动股价大幅走高。

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Can-Fite submits Phase 2 Lowe syndrome trial protocol for Piclidenoson to Italy hospital](https://longbridge.com/en/news/294682694.md)
- [Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients](https://longbridge.com/en/news/291432421.md)
- [Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting](https://longbridge.com/en/news/278625962.md)
- [Can-Fite BioPharma Adjourns 2026 Shareholder Meeting for Lack of Quorum](https://longbridge.com/en/news/287976129.md)
- [Biggest stock movers Thursday: FIZZ, CANF, and more](https://longbridge.com/en/news/291525078.md)